Literature DB >> 1637661

Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice.

L M Ching1, W R Joseph, B C Baguley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1637661      PMCID： PMC1977882          DOI： 10.1038/bjc.1992.228

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  19 in total

Review 1.  Flavone acetic acid--preclinical and clinical activity.

Authors:  D J Kerr; S B Kaye
Journal:  Eur J Cancer Clin Oncol       Date:  1989-09

2.  Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.

Authors:  R L Hornung; T C Back; D S Zaharko; W J Urba; D L Longo; R H Wiltrout
Journal:  J Immunol       Date:  1988-11-15       Impact factor: 5.422

3.  Blood flow failure as a major determinant in the antitumor action of flavone acetic acid.

Authors:  L J Zwi; B C Baguley; J B Gavin; W R Wilson
Journal:  J Natl Cancer Inst       Date:  1989-07-05       Impact factor: 13.506

4.  Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid.

Authors:  L L Thomsen; L M Ching; B C Baguley
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

5.  Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid.

Authors:  G Pratesi; M Rodolfo; G Rovetta; G Parmiani
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

6.  Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice.

Authors:  L L Thomsen; L M Ching; L Zhuang; J B Gavin; B C Baguley
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

7.  Interferon-gamma and tumor necrosis factor induce the L-arginine-dependent cytotoxic effector mechanism in murine macrophages.

Authors:  J C Drapier; J Wietzerbin; J B Hibbs
Journal:  Eur J Immunol       Date:  1988-10       Impact factor: 5.532

8.  Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy.

Authors:  J L Evelhoch; M C Bissery; G G Chabot; N E Simpson; C L McCoy; L K Heilbrun; T H Corbett
Journal:  Cancer Res       Date:  1988-09-01       Impact factor: 12.701

9.  The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity.

Authors:  M J Berendt; R J North; D P Kirstein
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307

10.  Anti-tumour activity of flavone acetic acid (NSC 347512) in mice--influence of immune status.

Authors:  M C Bibby; R M Phillips; J A Double; G Pratesi
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640
View more
  12 in total

1.  Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation.

Authors:  Jing Sun; Liang-Chuan S Wang; Zvi G Fridlender; Veena Kapoor; Guanjun Cheng; Lai-Ming Ching; Steven M Albelda
Journal:  Biochem Pharmacol       Date:  2011-07-26       Impact factor: 5.858

Review 2.  The biology of the combretastatins as tumour vascular targeting agents.

Authors:  Gillian M Tozer; Chryso Kanthou; Charles S Parkins; Sally A Hill
Journal:  Int J Exp Pathol       Date:  2002-02       Impact factor: 1.925

3.  Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours.

Authors:  L M Ching; W R Joseph; L Zhuang; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA.

Authors:  K Henare; L Wang; L-C S Wang; L Thomsen; S Tijono; C-J J Chen; S Winkler; P R Dunbar; C Print; L-M Ching
Journal:  Br J Cancer       Date:  2012-03-13       Impact factor: 7.640

5.  In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug.

Authors:  K Grosios; S E Holwell; A T McGown; G R Pettit; M C Bibby
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

Review 6.  Making the most of rodent tumour systems in cancer drug discovery.

Authors:  M C Bibby
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

7.  Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.

Authors:  Z Cao; W R Joseph; W L Browne; K G Mountjoy; B D Palmer; B C Baguley; L M Ching
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

8.  Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

Authors:  S M Tijono; K Guo; K Henare; B D Palmer; L-C S Wang; S M Albelda; L-M Ching
Journal:  Br J Cancer       Date:  2013-03-12       Impact factor: 7.640

9.  Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.

Authors:  C J Lash; A E Li; M Rutland; B C Baguley; L J Zwi; W R Wilson
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

10.  Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid.

Authors:  A L Laws; A M Matthew; J A Double; M C Bibby
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.